Merck: Data show glucose-lowering efficacy of Januvia in type 2 diabetes

By E. Janene Geiss

Philadelphia, Sept. 14 - Merck & Co., Inc. said Thursday that new study data demonstrated a significant mean placebo-subtracted reduction in glucose A1C(1) of 2.1% from a mean baseline A1C of 8.8% with Januvia (sitagliptin phosphate) at 50 mg twice daily with 1,000 mg of metformin, a commonly used diabetes therapy, in patients off therapy at randomization.

This study included another arm with Januvia and a lower dose of metformin and also monotherapy and placebo arms, and full results will be presented later this year. Januvia is the Whitehouse Station, N.J.-based pharmaceutical company's investigational oral medicine for type 2 diabetes, according to a news release.

The data was presented Thursday at the annual meeting of the European Association for the Study of Diabetes in Copenhagen.

In this study, simultaneous treatment with Januvia and metformin was generally well-tolerated and showed no meaningful differences in tolerability compared to metformin alone.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.